Shares Magazine
38.10p-1.00 (-2.56%)08 Dec 2025, 08:10
Jump to:
Novacyt S.A. Fundamentals
| Company Name | Novacyt S.A. | Last Updated | 2025-12-08 |
|---|---|---|---|
| Industry | Medical Devices | Sector | Healthcare |
| Shares in Issue | 70.626 m | Market Cap | £26.91 m |
| PE Ratio | 1.19 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.59 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.1740 | Debt Equity Ratio | 0.2446 |
| Asset Equity Ratio | 1.5407 | Cash Equity Ratio | 0.5807 |
| Quick Ratio | 4.1678 | Current Ratio | 5.03 |
| Price To Book Value | 0.6762 | ROCE | 0 |
Novacyt S.A. Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Novacyt S.A. Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | £10.70 m | £15.22 m | £3.27 m |
| Intangible Assets | £20.24 m | £31.68 m | £9.77 m |
| Investments | £25,000.00 | £57,000.00 | 0 |
| Total Fixed Assets | £31.26 m | £47.37 m | £13.66 m |
| Stocks | £2.27 m | £3.02 m | £3.03 m |
| Debtors | £3.71 m | £27.49 m | £25.35 m |
| Cash & Equivalents | £30.46 m | £44.06 m | £86.98 m |
| Other Assets | £286,000.00 | £413,000.00 | £624,000.00 |
| Total Assets | £70.63 m | £133.81 m | £140.90 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | £6.22 m | £29.57 m | £24.24 m |
| Creditors after 1 year | £16.53 m | £17.01 m | £1.45 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £22.75 m | £46.57 m | £25.68 m |
| Net assets | £47.88 m | £87.24 m | £115.22 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | £4.05 m | £4.05 m | £4.05 m |
| Share Premium | £50.67 m | £50.67 m | £50.67 m |
| Profit / Loss | -£39.43 m | -£24.46 m | -£20.05 m |
| Other Equity | £47.88 m | £87.24 m | £115.22 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £47.88 m | £87.24 m | £115.22 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | £0.18 | £0.13 | £0.00 |
| Debt-to-Equity | £0.22 | £0.14 | £0.00 |
| Assets / Equity | 1.5407 | 1.5407 | 1.5407 |
| Cash / Equity | 0.5807 | 0.5807 | 0.5807 |
| EPS | -£0.42 | -£0.26 | -£0.30 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -£9.15 m | -£22.38 m | -£13.73 m |
| Cashflow before financing | -£10.89 m | -£25.47 m | -£14.24 m |
| Increase in Cash | -£13.52 m | -£42.89 m | -£14.82 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | £19.63 m | £10.62 m | £21.04 m |
| Cost of sales | -£12.44 m | £7.13 m | £15.29 m |
| Gross Profit | £32.07 m | £3.49 m | £5.75 m |
| Operating Profit | -£37.34 m | -£25.45 m | -£23.39 m |
| Pre-Tax profit | -£39.43 m | -£24.46 m | -£20.05 m |
Novacyt S.A. Company Background
| Sector | Healthcare |
|---|---|
| Activities | Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment. |
| Latest Interim Date | 30 Sep 2025 |
| Latest Fiscal Year End Date | 30 Apr 2025 |
Novacyt S.A. Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-07-29 | Mr. Graham D. Mullis | Executive Director,Chief Executive Officer |
| 2024-04-30 | Dr. Andrew John William Heath | Non-Executive Director,Senior Independent Director |
| 2022-12-07 | Dr. Edwin Snape | Non-Executive Director |
| 2023-05-26 | Mr. Anthony Stephen Dyer | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-10-01 | Mr. James Christopher Wakefield | Non-Executive Director,Chairman |
| 2025-05-29 | Mr. Jean-Pierre Jacques Crinelli | Non-Executive Director |
| 2025-05-29 | Mr. Lyn Dafydd Rees | Executive Director,Chief Executive Officer |
| 2025-05-29 | Dr. Joanne Nicola Mason | Executive Director,Chief Scientific Officer |
| 2025-09-10 | Mr. James McCarthy | Executive Director,Interim Chief Executive Officer and Chief Financial Officer |
| 2022-11-10 | Mr. David James Allmond | Executive Director,Chief Executive Officer |
| 2025-05-29 | Mr. Steven Michael Gibson | Executive Director,Chief Financial Officer |
Novacyt S.A. Contact Details
| Company Name | Novacyt SA |
|---|---|
| Address | 13, Avenue Morane Saulnier, Velizy-Villacoublay, 78140 |
| Telephone | +33 139465104 |
| Website | https://www.novacyt.com |
Novacyt S.A. Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Kainos Group PLC | 1,161.00 | 7.20 |
| Trustpilot Group PLC | 153.90 | 5.12 |
| Baltic Classifieds Group PLC | 184.20 | 5.02 |
| Oxford Nanopore Technologies PLC | 128.90 | 3.37 |
| Oxford Biomedica PLC | 637.50 | 2.99 |
| Prudential PLC | 1,102.82 | 2.30 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Sdcl Efficiency Income Trust PLC | 51.91 | -17.48 |
| Unilever PLC | 4,232.00 | -5.03 |
| Future PLC | 612.00 | -3.47 |
| Unite Group PLC | 513.50 | -3.11 |
| Aston Martin Lagonda Global Holdings PLC | 63.60 | -2.83 |
| Rotork PLC | 333.00 | -2.35 |